Pfizer expects 24% of the U.S. population, or about 82 million people, to receive COVID-19 shots this year, CFO David Denton said at a conference on Monday, reiterating the vaccine maker’s estimates from earlier this year.
The U.S. Food and Drug Administration has authorized updated COVID vaccines from Pfizer and its partner BioNTech as well as from Moderna, as the country prepares to start a fall vaccination campaign. A third vaccine from Novavax is also under review.